Medicis (MRX) Gets Verbal Notice of Allowance for ZYCLARA Patent on Actinic Keratosis
Tweet Send to a Friend
On May 16, 2012, Medicis Pharmaceutical Corporation (NYSE": MRX) received verbal notification that the United States Patent and Trademark Office expects to issue Notices of Allowance for the Company’s United States patent applications directed to the use of ZYCLARA for the treatment of actinic keratosis.
The patent applications are U.S. Application Nos. 13/179,315, entitled 2 x 2 x 2 Week Treatment Regimen for Treating Actinic Keratosis with Pharmaceutical Compositions Formulated with 2.5% Imiquimod, 13/181,499, entitled 2 x 2 x 2 Week Dosing Regimen for Treating Actinic Keratosis with Pharmaceutical Compositions Formulated with 3.75% Imiquimod, and 13/182,433, entitled Method of Treating Actinic Keratosis with 3.75% Imiquimod Cream. As of May 18, 2012, the intended issuance of the Notices of Allowance was reflected on the USPTO’s public Patent Application Information Retrieval (PAIR) website. The Company expects to receive the formal Notices of Allowance from the USPTO in the second quarter of 2012.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The patent applications are U.S. Application Nos. 13/179,315, entitled 2 x 2 x 2 Week Treatment Regimen for Treating Actinic Keratosis with Pharmaceutical Compositions Formulated with 2.5% Imiquimod, 13/181,499, entitled 2 x 2 x 2 Week Dosing Regimen for Treating Actinic Keratosis with Pharmaceutical Compositions Formulated with 3.75% Imiquimod, and 13/182,433, entitled Method of Treating Actinic Keratosis with 3.75% Imiquimod Cream. As of May 18, 2012, the intended issuance of the Notices of Allowance was reflected on the USPTO’s public Patent Application Information Retrieval (PAIR) website. The Company expects to receive the formal Notices of Allowance from the USPTO in the second quarter of 2012.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- EMA Approves MAA for Gilead's (GILD) Sofosbuvir
- OSI Systems (OSIS) Unit Issued Notice of Proposed Debarment from U.S. DHS
- Sanofi (SNY), Regeneron (REGN) Report Publication of Positive Dupilumab Phase 2a Data
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
